Cabenuva is a long-acting injectable medication used to treat HIV-1 infection in adults. It's a combination of two antiretroviral drugs: cabotegravir and rilpivirine.

Key features:

• Long-acting: Cabenuva is administered as an injection every two months, providing long-term HIV suppression without daily oral medication.
• Effective: Clinical trials have shown Cabenuva to be highly effective in suppressing HIV-1 viral load to undetectable levels.
• Convenient: The long-acting nature of Cabenuva reduces the need for daily medication, improving adherence and potentially reducing the risk of transmission.
• Suitable for people living with HIV: Cabenuva is approved for adults living with HIV-1 who are virologically suppressed and have no history of treatment failure.